Retention of structure, antigenicity, and biological function of pneumococcal surface protein A (PspA) released from polyanhydride nanoparticles

Shannon L. Haughney, Latrisha K. Petersen, Amy D. Schoofs, Amanda E. Ramer-Tait, Janice D. King, David E. Briles, Michael J. Wannemuehler, Balaji Narasimhan

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Pneumococcal surface protein A (PspA) is a choline-binding protein which is a virulence factor found on the surface of all Streptococcus pneumoniae strains. Vaccination with PspA has been shown to be protective against a lethal challenge with S. pneumoniae, making it a promising immunogen for use in vaccines. Herein the design of a PspA-based subunit vaccine using polyanhydride nanoparticles as a delivery platform is described. Nanoparticles based on sebacic acid (SA), 1,6-bis-(p-carboxyphenoxy)hexane (CPH) and 1,8-bis-(p-carboxyphenoxy)-3,6-dioxaoctane (CPTEG), specifically 50:50 CPTEG:CPH and 20:80 CPH:SA, were used to encapsulate and release PspA. The protein released from the nanoparticle formulations retained its primary and secondary structure as well as its antigenicity. The released PspA was also biologically functional based on its ability to bind to apolactoferrin and prevent its bactericidal activity against Escherichia coli. When the PspA nanoparticle formulations were administered subcutaneously to mice they elicited a high titer and high avidity anti-PspA antibody response. Together these studies provide a framework for the rational design of a vaccine against S. pneumoniae based on polyanhydride nanoparticles.

Original languageEnglish (US)
Pages (from-to)8262-8271
Number of pages10
JournalActa Biomaterialia
Volume9
Issue number9
DOIs
StatePublished - Sep 1 2013

Fingerprint

Polyanhydrides
Nanoparticles
Proteins
Hexanes
Vaccines
Streptococcus pneumoniae
Hexane
Subunit Vaccines
Virulence Factors
Acids
Choline
pneumococcal surface protein A
Escherichia coli
Antibody Formation
Antibodies
Carrier Proteins
Vaccination

Keywords

  • Nanoparticle
  • Pneumococcal surface protein A
  • Polyanhydride
  • Streptococcus pneumoniae
  • Vaccine

ASJC Scopus subject areas

  • Biotechnology
  • Biomaterials
  • Biochemistry
  • Biomedical Engineering
  • Molecular Biology

Cite this

Retention of structure, antigenicity, and biological function of pneumococcal surface protein A (PspA) released from polyanhydride nanoparticles. / Haughney, Shannon L.; Petersen, Latrisha K.; Schoofs, Amy D.; Ramer-Tait, Amanda E.; King, Janice D.; Briles, David E.; Wannemuehler, Michael J.; Narasimhan, Balaji.

In: Acta Biomaterialia, Vol. 9, No. 9, 01.09.2013, p. 8262-8271.

Research output: Contribution to journalArticle

Haughney, Shannon L. ; Petersen, Latrisha K. ; Schoofs, Amy D. ; Ramer-Tait, Amanda E. ; King, Janice D. ; Briles, David E. ; Wannemuehler, Michael J. ; Narasimhan, Balaji. / Retention of structure, antigenicity, and biological function of pneumococcal surface protein A (PspA) released from polyanhydride nanoparticles. In: Acta Biomaterialia. 2013 ; Vol. 9, No. 9. pp. 8262-8271.
@article{d5fcb71d4cf04f6da4db2517a358f4bd,
title = "Retention of structure, antigenicity, and biological function of pneumococcal surface protein A (PspA) released from polyanhydride nanoparticles",
abstract = "Pneumococcal surface protein A (PspA) is a choline-binding protein which is a virulence factor found on the surface of all Streptococcus pneumoniae strains. Vaccination with PspA has been shown to be protective against a lethal challenge with S. pneumoniae, making it a promising immunogen for use in vaccines. Herein the design of a PspA-based subunit vaccine using polyanhydride nanoparticles as a delivery platform is described. Nanoparticles based on sebacic acid (SA), 1,6-bis-(p-carboxyphenoxy)hexane (CPH) and 1,8-bis-(p-carboxyphenoxy)-3,6-dioxaoctane (CPTEG), specifically 50:50 CPTEG:CPH and 20:80 CPH:SA, were used to encapsulate and release PspA. The protein released from the nanoparticle formulations retained its primary and secondary structure as well as its antigenicity. The released PspA was also biologically functional based on its ability to bind to apolactoferrin and prevent its bactericidal activity against Escherichia coli. When the PspA nanoparticle formulations were administered subcutaneously to mice they elicited a high titer and high avidity anti-PspA antibody response. Together these studies provide a framework for the rational design of a vaccine against S. pneumoniae based on polyanhydride nanoparticles.",
keywords = "Nanoparticle, Pneumococcal surface protein A, Polyanhydride, Streptococcus pneumoniae, Vaccine",
author = "Haughney, {Shannon L.} and Petersen, {Latrisha K.} and Schoofs, {Amy D.} and Ramer-Tait, {Amanda E.} and King, {Janice D.} and Briles, {David E.} and Wannemuehler, {Michael J.} and Balaji Narasimhan",
year = "2013",
month = "9",
day = "1",
doi = "10.1016/j.actbio.2013.06.006",
language = "English (US)",
volume = "9",
pages = "8262--8271",
journal = "Acta Biomaterialia",
issn = "1742-7061",
publisher = "Elsevier BV",
number = "9",

}

TY - JOUR

T1 - Retention of structure, antigenicity, and biological function of pneumococcal surface protein A (PspA) released from polyanhydride nanoparticles

AU - Haughney, Shannon L.

AU - Petersen, Latrisha K.

AU - Schoofs, Amy D.

AU - Ramer-Tait, Amanda E.

AU - King, Janice D.

AU - Briles, David E.

AU - Wannemuehler, Michael J.

AU - Narasimhan, Balaji

PY - 2013/9/1

Y1 - 2013/9/1

N2 - Pneumococcal surface protein A (PspA) is a choline-binding protein which is a virulence factor found on the surface of all Streptococcus pneumoniae strains. Vaccination with PspA has been shown to be protective against a lethal challenge with S. pneumoniae, making it a promising immunogen for use in vaccines. Herein the design of a PspA-based subunit vaccine using polyanhydride nanoparticles as a delivery platform is described. Nanoparticles based on sebacic acid (SA), 1,6-bis-(p-carboxyphenoxy)hexane (CPH) and 1,8-bis-(p-carboxyphenoxy)-3,6-dioxaoctane (CPTEG), specifically 50:50 CPTEG:CPH and 20:80 CPH:SA, were used to encapsulate and release PspA. The protein released from the nanoparticle formulations retained its primary and secondary structure as well as its antigenicity. The released PspA was also biologically functional based on its ability to bind to apolactoferrin and prevent its bactericidal activity against Escherichia coli. When the PspA nanoparticle formulations were administered subcutaneously to mice they elicited a high titer and high avidity anti-PspA antibody response. Together these studies provide a framework for the rational design of a vaccine against S. pneumoniae based on polyanhydride nanoparticles.

AB - Pneumococcal surface protein A (PspA) is a choline-binding protein which is a virulence factor found on the surface of all Streptococcus pneumoniae strains. Vaccination with PspA has been shown to be protective against a lethal challenge with S. pneumoniae, making it a promising immunogen for use in vaccines. Herein the design of a PspA-based subunit vaccine using polyanhydride nanoparticles as a delivery platform is described. Nanoparticles based on sebacic acid (SA), 1,6-bis-(p-carboxyphenoxy)hexane (CPH) and 1,8-bis-(p-carboxyphenoxy)-3,6-dioxaoctane (CPTEG), specifically 50:50 CPTEG:CPH and 20:80 CPH:SA, were used to encapsulate and release PspA. The protein released from the nanoparticle formulations retained its primary and secondary structure as well as its antigenicity. The released PspA was also biologically functional based on its ability to bind to apolactoferrin and prevent its bactericidal activity against Escherichia coli. When the PspA nanoparticle formulations were administered subcutaneously to mice they elicited a high titer and high avidity anti-PspA antibody response. Together these studies provide a framework for the rational design of a vaccine against S. pneumoniae based on polyanhydride nanoparticles.

KW - Nanoparticle

KW - Pneumococcal surface protein A

KW - Polyanhydride

KW - Streptococcus pneumoniae

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=84880924697&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880924697&partnerID=8YFLogxK

U2 - 10.1016/j.actbio.2013.06.006

DO - 10.1016/j.actbio.2013.06.006

M3 - Article

C2 - 23774257

AN - SCOPUS:84880924697

VL - 9

SP - 8262

EP - 8271

JO - Acta Biomaterialia

JF - Acta Biomaterialia

SN - 1742-7061

IS - 9

ER -